Is hypogonadism more common in autoimmune polyglandular syndrome type 1 (APS‑1) or type 2 (APS‑2)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Hypogonadism is More Common in APS-1 Than APS-2

Hypogonadism occurs as a major component of autoimmune polyglandular syndrome type 1 (APS-1), where it is a constant feature affecting the majority of patients, while it is less frequently seen in APS-2. 1, 2

Key Differences Between APS-1 and APS-2 Regarding Hypogonadism

APS-1 (Higher Frequency)

In APS-1, hypogonadism is one of the defining endocrinopathies:

  • Primary amenorrhea or oligomenorrhea with infertility are constant features in patients with this rare, recessively inherited syndrome 1
  • Ovarian failure occurs in 40.8% of women with APS-1 according to Italian cohort data 3
  • The hypogonadism is hypergonadotropic (primary gonadal failure) with elevated FSH/LH levels
  • Associated with autoantibodies against steroid-producing cells, including antibodies to 17α-hydroxylase and side-chain cleavage enzyme 1
  • Caused by mutations in the AIRE gene (chromosome 21q22.3), which disrupts normal immune tolerance 2

APS-2 (Lower Frequency)

In APS-2, hypogonadism is a less prominent feature:

  • May be seen as part of the syndrome but is not a defining component 1
  • APS-2 is primarily characterized by combinations of autoimmune thyroid disease, type 1 diabetes, vitiligo, pernicious anemia, and Addison's disease
  • When hypogonadism does occur in APS-2, it typically presents alongside these other more common manifestations 4, 5

Clinical Implications

For APS-1 Patients:

  • Screen all patients for hypogonadism with FSH, LH, and sex hormone levels
  • In females, monitor for premature ovarian insufficiency—consider CYP11A1 autoantibodies, though predictive value is limited 3
  • Counsel about fertility preservation options (ovarian tissue cryopreservation) as follicular function may persist for several years after diagnosis 3
  • Provide hormone replacement therapy for symptomatic hypogonadism

For APS-2 Patients:

  • Hypogonadism screening is still warranted but less urgent than in APS-1
  • Focus primarily on screening for the more common APS-2 components (thyroid disease, diabetes, adrenal insufficiency)
  • If hypogonadism is present, it typically manifests as primary hypogonadism 4, 5

Important Caveats

The presence of steroid cell autoantibodies outside the context of a defined autoimmune polyglandular syndrome is rare 1. Parents who are heterozygous carriers of AIRE gene mutations do not develop APS-1 features or autoantibodies, so isolated hypogonadism without other APS-1 features is unlikely to be AIRE-related 1.

References

1
Research

Autoimmune hypogonadism as part of an autoimmune polyglandular syndrome.

Journal of the Society for Gynecologic Investigation, 2001

Related Questions

In a patient with systemic lupus erythematosus and Graves disease, how can one differentiate autoimmune polyendocrine syndrome type II from type III?
What are the subtypes of autoimmune polyendocrine syndrome type III, and which subtype applies to a patient with Graves disease (autoimmune thyroid disease) and systemic lupus erythematosus?
How can one differentiate autoimmune polyendocrine syndrome (type II) from antiphospholipid antibody syndrome in a patient with systemic lupus erythematosus and Graves disease?
What is the diagnostic plan and management of Autoimmune Polyendocrine Syndrome (APS)?
In a patient with persistent asthma and a total serum IgE level of 224 IU/mL, could this represent allergic bronchopulmonary aspergillosis (ABPA)?
A 25-year-old woman presents with hearing loss after diving, without pain, fever, chills, or ear discharge. What is the appropriate management?
What edoxaban dose is equivalent to apixaban 2.5 mg twice daily in a patient meeting dose‑reduction criteria?
In a patient with hepatosplenomegaly, platelet count of 30 × 10⁹/L, 15‑day fever, and moderate ascites, what is the next step in management?
Can a nuchal translucency (NT) scan be performed transvaginally?
What precipitating factors can cause a patient with stable valvular heart disease to decompensate into heart failure?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.